Werewolf Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Werewolf Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-35.8%
Buyback Yield
| Total Shareholder Yield | -35.8% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry?
Nov 14
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?
Jul 31Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1
Jul 01Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding
Jun 04Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Apr 04Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Feb 07Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise
Dec 09Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates
Sep 30Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 13We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
Jul 08Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Mar 24Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Dec 09Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if HOWL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HOWL's dividend payments have been increasing.
Dividend Yield vs Market
| Werewolf Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (HOWL) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (HOWL) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate HOWL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HOWL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate HOWL's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as HOWL has not reported any payouts.